Amolyt Pharma aims to leverage the extensive experience of its team in developing therapeutic peptides to provide groundbreaking treatments for individuals affected by rare endocrine and metabolic disorders. The company's pipeline encompasses AZP-3601, a parathyroid hormone analog targeting hypoparathyroidism, and AZP-3404, a unique peptide with a novel mechanism of action that has the potential to normalize fat and glucose metabolism. With a strong global network in the field of endocrinology, Amolyt Pharma is well-prepared for future milestones and the potential addition of new programs.
Amolyt Pharma
Headquarters
France